Intellia Trial to Test Gene-editing Therapy NTLA-2002 in New Zealand
The New Zealand Medicines and Medical Devices Safety Authority has authorized Intellia Therapeutics to launch a Phase 1/2 trial testing NTLA-2002, its investigational gene-editing therapy, in adults with hereditary angioedema (HAE). According to the company, patient enrollment is expected to start by the end of the year. Data…